How Kariko And Weissman Pioneered The Mrna Vaccine?

The story of the mRNA vaccine is not a story about a single “eureka” moment. It is a story about two researchers who refused to give up on an idea that most of the scientific world had dismissed. Katalin Karikó and Drew Weissman met at the University of Pennsylvania in the late 1990s. Their collaboration, built on a shared curiosity about how cells work, laid the foundation for the COVID-19 vaccines that would eventually save millions of lives. They solved a problem that had stumped scientists for decades: how to get synthetic messenger RNA into the human body without triggering a massive, destructive immune response.

What Was the Problem With Messenger RNA?

Messenger RNA, or mRNA, is a single-stranded molecule that carries genetic instructions from DNA to the cell’s protein-making machinery. In theory, scientists had long known that if you could deliver a synthetic mRNA into cells, you could instruct those cells to produce any protein you wanted. For a vaccine, that meant you could tell the body to make a harmless piece of a virus, and the immune system would learn to attack the real virus later.

The theory was sound. The practice was a disaster.

When researchers injected synthetic mRNA into animals in the 1990s, the animals got sick. Their immune systems treated the foreign mRNA as a sign of viral invasion and mounted a powerful inflammatory response. The animals often died. The scientific community concluded that mRNA therapy was a dead end. It was too dangerous, too unstable, and too expensive to produce.

Karikó was one of the few scientists who did not accept that conclusion. She had spent years studying RNA and believed the problem was not with mRNA itself, but with how it was being made. She suspected that the synthetic mRNA was missing a modification that natural mRNA has.

How Did Karikó and Weissman Meet?

Katalin Karikó was a Hungarian biochemist who had moved to the United States in the 1980s. By the late 1990s, she was a research assistant professor at the University of Pennsylvania. That title sounds respectable, but it was not a secure position. She was struggling to get grant funding. Her work on mRNA was repeatedly rejected because reviewers did not believe it would ever lead to a useful therapy.

Drew Weissman was an immunologist who had recently joined the same university. He was studying dendritic cells, which are immune cells that help coordinate the body’s response to infection. He needed a way to make those cells produce specific proteins so he could study how the immune system reacts.

Karikó and Weissman met by chance at a photocopy machine in the university’s medical school building. Karikó asked Weissman what he was working on. When he mentioned dendritic cells, she told him she could make mRNA that would teach those cells to produce any protein he wanted. Weissman was skeptical but intrigued. That conversation led to a collaboration that lasted for years.

What Was the Key Discovery About Uridine?

The breakthrough came when Karikó and Weissman started looking closely at the chemical structure of RNA. They knew that natural RNA contains modified building blocks, and they suspected these modifications were important.

RNA is made of four basic building blocks called nucleotides: adenine, cytosine, guanine, and uracil. Karikó noticed that natural RNA contains a modified version of uracil called pseudouridine. Synthetic mRNA made in a lab used plain, unmodified uracil. She hypothesized that this difference was what made the immune system attack the synthetic mRNA.

In 2005, Karikó and Weissman published a landmark study. They showed that when they replaced uracil with pseudouridine in synthetic mRNA, the immune system no longer attacked it. The modified mRNA was able to slip into cells and produce proteins without causing the dangerous inflammation that had killed earlier experiments.

This was the foundational discovery. It was not a vaccine. It was not even a drug. But it was the key that unlocked the entire field of mRNA medicine.

Why Did the Discovery Take So Long to Gain Recognition?

The 2005 paper was published in a respected journal, but it did not immediately change the world. The scientific community was slow to embrace the idea. Karikó and Weissman’s work was initially viewed as interesting basic science, not as a practical breakthrough.

There were several reasons for this. First, the field of RNA research was still small. Second, many scientists doubted that mRNA could ever be delivered safely and effectively into humans. Third, the pharmaceutical industry had largely abandoned mRNA research after the failed animal experiments of the 1990s.

Karikó continued to face professional challenges. She struggled to get funding and was eventually demoted at the University of Pennsylvania. Despite these setbacks, she and Weissman continued their collaboration. They published follow-up studies showing that modified mRNA produced even more protein than unmodified mRNA, which meant it was not just safer but also more effective.

The turning point came in 2013 when a group of researchers at the biotech company Moderna, along with a team in Germany that would later become BioNTech, began testing mRNA vaccines in humans. They were building directly on the foundation that Karikó and Weissman had laid.

How Did the Discovery Lead to the COVID-19 Vaccines?

When the genetic sequence of the SARS-CoV-2 virus was published in January 2020, vaccine developers were ready. The mRNA technology that Karikó and Weissman had spent two decades perfecting could be adapted quickly.

Instead of growing the virus in eggs or weakening it in a lab, which takes months, scientists could design an mRNA sequence that encoded the virus’s spike protein. They could produce that mRNA in large quantities and package it in lipid nanoparticles, which are tiny fat bubbles that protect the mRNA and help it enter cells.

Once inside cells, the mRNA instructs the cells to produce the spike protein. The immune system recognizes this protein as foreign and mounts a defense. If the person later encounters the real virus, their immune system is ready to attack it.

The Pfizer-BioNTech and Moderna vaccines, both authorized for emergency use in December 2020, were the first mRNA vaccines ever approved for use in humans. Clinical trials showed they were remarkably effective at preventing severe illness and death from COVID-19.

What Recognition Did Karikó and Weissman Receive?

Karikó and Weissman received the Nobel Prize in Physiology or Medicine in 2023. The Nobel committee cited their discovery of “nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.”

The recognition was long overdue. Karikó had spent decades working on a fringe idea that most experts had written off. She endured years of grant rejections, professional setbacks, and doubt from colleagues. Her persistence is now cited as one of the most important examples of scientific resilience in modern medicine.

Weissman, who was more established in the academic world, also faced skepticism. But both researchers continued their work because they believed in the underlying science, not because they expected fame or fortune.

What Does This Mean for the Future of Medicine?

The success of the mRNA vaccines has opened a new era in medicine. The technology is not limited to infectious diseases. Researchers are now testing mRNA-based treatments for cancer, autoimmune diseases, and genetic disorders.

For cancer, the idea is to create personalized mRNA vaccines that teach the immune system to recognize and attack tumor cells. For genetic diseases, mRNA could potentially be used to produce missing or defective proteins. Clinical trials are underway, but it is important to be clear: these treatments are still experimental. No mRNA cancer vaccine has been approved for general use.

What is certain is that the basic technology works. Karikó and Weissman proved that synthetic mRNA can be safely delivered into human cells and used to produce functional proteins. The COVID-19 vaccines demonstrated that this platform can be scaled up rapidly and deployed globally. That is a genuine scientific achievement, not marketing hype.

What Are the Limits of the mRNA Platform?

mRNA vaccines are not without limitations. They require extremely cold storage temperatures, which creates logistical challenges in low-resource settings. The Pfizer vaccine, for example, needed to be stored at ultra-low temperatures, although later formulations were less demanding.

The technology is also relatively expensive to produce compared to some traditional vaccines. And while the COVID-19 vaccines were highly effective, they are not perfect. Protection wanes over time, and the vaccines were less effective against some newer variants, particularly at preventing infection rather than severe disease.

These are real limitations, and honest discussions about them are important. But they do not diminish the core achievement. Karikó and Weissman solved a fundamental biological problem. Everything else is engineering.